Is Daxxify FDA Approved? What MedSpa Owners Need to Know

Yes, Daxxify is FDA approved. The product received FDA clearance in September 2023 for the treatment of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. It is the first and only botulinum toxin product formulated with a peptide stabilizer technology, which is the key difference from Botox and other competitors.

How Daxxify Differs from Botox

The core distinction is longevity. Daxxify's peptide-stabilizer formulation allows results to last approximately 6 months, compared to Botox's typical 3–4 month duration. This longer window between treatments can appeal to patients seeking less frequent appointments and potentially lower annual costs.

Both products use botulinum toxin type A and work the same way—by relaxing muscles that create expression lines. However:

• Daxxify does not require reconstitution with saline before use; it comes ready-to-inject
• The stabilizer technology may reduce the need for frequent touch-ups
• Onset is comparable to Botox (3–7 days, with full results at 2 weeks)

FDA Approval Scope

Daxxify is currently approved only for glabellar lines. If you're considering it for your practice, verify with the manufacturer and your state board whether off-label use for other areas (crow's feet, forehead, etc.) aligns with your compliance and insurance protocols. FDA approval does not dictate off-label practice, but documentation and informed consent are essential.

Practice Considerations

From a business angle, the longer duration can reduce patient visit frequency but may also extend the sales cycle. Pricing, reimbursement, and patient education about the difference will shape adoption. Verify current pricing and any supply considerations with your distributor, as market dynamics continue to evolve.

Always confirm current approval status, indications, and any updates with the FDA or manufacturer, as regulatory status can change.